Beruzatatug Pelitecan

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of beruzatatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3) conjugated via a tumor microenvironment (TME) activable protease-cleavable tripeptide linker to a cytotoxic DNA topoisomerase I inhibitor YL0010014, with potential antineoplastic activity. Upon administration of beruzatatug pelitecan, beruzatatug moiety targets and binds to HER3 expressed on tumor cells. Upon proteolytic cleavage in the TME and the release of YL0010014, the topoisomerase I inhibitor targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA and resulting in DNA breaks, inhibition of DNA replication and apoptosis in HER3-expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.

**Synonyms:** - Anti-HER3 ADC YL202 - Anti-HER3 Antibody-drug Conjugate BNT326 - Anti-HER3 Antibody-drug Conjugate YL202 - BERUZATATUG PELITECAN - BNT 326 - BNT-326 - BNT326 - Beruzatatug-based ADC YL202 - HER3-targeting Antibody-drug Conjugate YL202 - YL 202 - YL-202 - YL202